Sanofi’s Phase 3 Study on Riliprubart for CIDP: A Potential Game-Changer

Sanofi SA ((SNY)), Sanofi ((SNYNF)), Sanofi ((DE:SNW)) announced an update on their ongoing clinical study.

Sanofi is conducting a Phase 3 study titled ‘A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)’. The study aims to evaluate the efficacy and safety of riliprubart compared to IVIg in adults with CIDP, a condition that affects the peripheral nerves. This study is significant as it could offer a new treatment option for CIDP patients.

The intervention being tested is riliprubart, a drug administered as an intravenous solution, compared against the standard IVIg treatment. The purpose of riliprubart is to provide a potentially more effective treatment for CIDP patients.

The study design is interventional, with a randomized, parallel assignment. It involves a double-blind treatment period followed by an open-label phase. The study employs quadruple masking, meaning that the participant, care provider, investigator, and outcomes assessor are all unaware of the treatment assignments. The primary purpose of the study is treatment-focused.

The study began on August 21, 2024, and is currently recruiting participants. The primary completion date is yet to be announced, but the last update was submitted on August 18, 2025. These dates are crucial as they guide the timeline for potential market entry of riliprubart.

The outcome of this study could significantly impact Sanofi’s stock performance and investor sentiment, as a successful result might position riliprubart as a leading treatment for CIDP. This development could also influence the competitive landscape, affecting other companies in the neurological treatment sector.

The study is ongoing, with further details available on the ClinicalTrials portal.